FMP
Enter
API Tools
Extras
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.95 USD
-0.02 (-0.404%)
WACOC
Price
4.95
Beta
Diluted Shares Outstanding
52.22M
Costof Debt
3.75
Tax Rate
After Tax Cost Of Debt
3.75
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
243.72M
Total Equity
258.48M
Total Capital
502.2M
Debt Weighting
48.53
Equity Weighting
51.47
Wacc
6.28
